More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$2.26B
EPS
-3.49
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
-2.475523
Previous close
$33.36
Today's open
$33.19
Day's range
$32.44 - $34.46
52 week range
$23.01 - $43.25
show more
CEO
Berndt Modig
Employees
129
Headquarters
Leiden,
Exchange
Nasdaq Global Select
Shares outstanding
69666453
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Wall Street Analysts See a 79.41% Upside in Pharvaris (PHVS): Can the Stock Really Move This High?
The mean of analysts' price targets for Pharvaris (PHVS) points to a 79.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Investment Research • Nov 16, 2026

Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update
ZUG, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the third quarter ending on September 30, 2026, and provided a business update.
GlobeNewsWire • Nov 12, 2026

Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
ZUG, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the oral and poster presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting, taking place November 12-16, 2026, in Phoenix, Arizona. The presentations include late-breaking results from the Phase 3 CHAPTER-3 study evaluating investigational oral deucrictibant extended-release (XR) tablet for prophylaxis of HAE attacks to be presented in the Distinguished Industry and Late-breaking Oral Abstracts sessions on Saturday, November 14 from 4:30 – 6:00 p.m. MST, as well as final long-term results from the prophylaxis Phase 2 open-label extension, additional analyses of the pivotal Phase 3 on-demand treatment study, clinical pharmacology data supporting the potential combined use of the XR and immediate-release (IR) formulations, a comprehensive assessment of deucrictibant's cardiovascular safety across the development program, and the real-world economic burden of HAE.
GlobeNewsWire • Nov 12, 2026

Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14 Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14
GlobeNewsWire • Oct 29, 2026

Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade
Bank of America Securities on Friday upgraded Pharvaris N.V. (NASDAQ:PHVS), citing an attractive entry point with clinical risk largely removed.
Benzinga • Oct 23, 2026

Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results of RAPIDe-3, a phase 3, global, randomized, double-blind, placebo-controlled crossover study evaluating oral deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment of HAE attacks in adolescents and adults have been published in The Lancet (Journal Impact Factor: 109.0).
GlobeNewsWire • Oct 8, 2026

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options
GlobeNewsWire • Oct 5, 2026

Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha • Sep 15, 2026

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.
Zacks Investment Research • Sep 15, 2026

Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win
Pharvaris N.V. maintains a 'Strong Buy' rating following pivotal phase 3 wins for both on-demand and prophylactic HAE therapies. PHVS achieved rapid symptom relief in RAPIDe-3 [median 1.28 hours, p
Seeking Alpha • Sep 9, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Pharvaris N.V. commission-free¹. Build wealth for the long term using automated trading and transfers.